What is MDXG's market cap?

$470.61M, based on the Nov 4 close of $3.23.

Does MiMedx Group pay a dividend?

No regular cash dividend has been paid in the last year.

How much of MDXG is sold short?

9.3M shares, 8.1% of float, as of Oct 15, 2026.

What sector is MDXG in?

Healthcare, in the Surgical Instruments industry.

NASDAQ · MDXGHealthcareSurgical Instruments

MiMedx Group, Inc (MDXG)

$3.23−0.77%

Close Nov 4, 2026 · split-adjusted

Nov 3, 2026$3.25▼ 56.78% in range

Nov 3, 2025Low $3.08 · High $7.96Nov 3, 2026

What changed · written from our data

As of Nov 4, 2026

MiMedx Group closed at $3.23 on Nov 4, down 0.77%, 59.5% below its 52-week closing high. Volume of 610.2K shares was 0.36× its 20-day average (below normal).

Split-adjusted performance: -30.2% over one month, -11.9% over six months, -57.1% over one year.

In the quarter ended Sep 30, 2026, revenue was $62.28M, down 45.2% from a year earlier, with a net margin of -13.9%.

Short interest was 9.3M shares at the Oct 15 settlement, down 1.1% from the prior report (8.1% of float, 9.1 days to cover).

Market cap$470.6M145.9M shares

Revenue · quarter$62.3M−45.2% YoY

Diluted EPS$-0.06−154.5% YoY

P/E · TTM—P/S 1.5×

Net margin-13.9%Gross 79.8%

Dividend yieldNone

52-week range3.08 – 7.96−59.5% from high

Volume610.2K0.36× 20-day avg

Volatility · 60d51.7%Annualised

Short % of float8.1%9.1 days to cover

Net cash$120.8MCash $120.8M

Next earnings—Not scheduled

Split-adjusted performance

1W −18.4%1M −30.2%3M −22.8%6M −11.9%YTD −52.4%1Y −57.1%3Y −49.0%5Y −50.8%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum43

Revenue growth2

Net margin44

Value (low P/E)—

Size59

Industry medians: 6-month return −4.4%, revenue growth +8.9%, net margin −8.2%, P/E 29.7×.

Short interest

Details →

Shares short9.3M−1.1% vs prior

Days to cover9.1Settled Oct 15

% of float8.1%

Short vol. 10d52.3%of daily volume

Closest peers by size in Surgical Instruments

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
MDXGMiMedx Group	$3.23	−0.77%	−11.9%	−45.2%	−13.9%	—	$470.6M
NPCENeuropace	$13.71	+11.37%	−24.3%	+17.1%	−27.2%	—	$470.6M	Compare
SSIISS Innovations International	$2.26	−2.92%	−44.4%	+39.4%	−19.1%	—	$453.5M	Compare
CERSCerus	$2.48	+5.77%	−4.4%	+6.3%	−0.9%	—	$498.8M	Compare
RCELAvita Medical	$16.18	+5.54%	+266.1%	+17.8%	−35.3%	—	$500.4M	Compare
SIShoulder Innovations	$21.14	+6.66%	+64.0%	—	−59.1%	—	$440.1M	Compare
CARLCarlsmed	$15.96	+10.83%	+62.2%	—	−55.5%	—	$435.8M	Compare
DCTHDelcath Systems	$14.94	+3.75%	+32.7%	+20.6%	9.2%	974.4	$518.4M	Compare
ANGOAngioDynamics	$12.58	+7.25%	+13.8%	+6.9%	−8.8%	—	$529.0M	Compare

News about MiMedx Group

All news →

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026GlobeNewswire Inc. · Oct 14, 2026▲ Positive MIMEDX to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · Sep 8, 2026▲ Positive

Quick answers

What does MiMedx Group do?: MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets.
What is MDXG's market cap?: $470.61M, based on the Nov 4 close of $3.23.
Does MiMedx Group pay a dividend?: No regular cash dividend has been paid in the last year.
How much of MDXG is sold short?: 9.3M shares, 8.1% of float, as of Oct 15, 2026.
What sector is MDXG in?: Healthcare, in the Surgical Instruments industry.

About MiMedx Group

MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.

HQ: Marietta, GA808 employeesListed Aug 22, 2007mimedx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology